Holen Sie sich die Stockscreener-App
4.195
1.08%
0.045
Vorhandelsmarkt:
4.19
-0.005
-0.12%
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
HC Wainwright Analysts Decrease Earnings Estimates for COYA - MarketBeat
Sell Signal: How much upside does Coya Therapeutics Inc have2026 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President a - pharmiweb.com
What is HC Wainwright's Estimate for COYA Q1 Earnings? - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating - TipRanks
Coya Therapeutics (COYA) Analyst Rating Reiterated at 'Buy' by H - GuruFocus
[EFFECT] Coya Therapeutics, In... | COYA SEC FilingForm EFFECT - Stock Titan
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
CEO Moves: Can Coya Therapeutics Inc sustain earnings growthInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn
2.52M-share resale registration by Coya Therapeutics (NASDAQ: COYA) after Jan 2026 placement - Stock Titan
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - Business Wire
COYA SEC FilingsCoya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Coya Therapeutics (COYA) Deepening Losses Challenge Bullish Growth Narrative After FY 2025 Results - simplywall.st
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD - TipRanks
CGTX PE Ratio & Valuation, Is CGTX Overvalued - Intellectia AI
Treasury Yields: Is Coya Therapeutics Inc impacted by rising ratesBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
COYA: Chardan Capital Maintains 'Buy' Rating with $14 Price Targ - GuruFocus
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Reports 2025 Financial Results and Advances ALS & FTD Clinical Trials with Strong Cash Position - Minichart
Coya Therapeutics: Advancing Treg-Based Therapies for Neurodegenerative and Autoimmune Diseases - Minichart
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - BioSpace
Coya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Coya Therapeutics Incfiles for resale of up to 2.5 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
Coya Therapeutics (NASDAQ: COYA) registers 2.52M private‑placement shares for resale - Stock Titan
Coya Therapeutics provides a corporate update and reports fiscal 2025 financial results - marketscreener.com
Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results - MarketBeat
Coya Therapeutics 2025 10-K: $7.95M Revenue; $(21.23)M Net Loss - TradingView
ALS Treg pipeline and runway into 2027 at Coya Therapeutics (NASDAQ: COYA) - Stock Titan
Coya Therapeutics (NASDAQ: COYA) reports 2025 results, funds runway into 2H 2027 - Stock Titan
Coya Therapeutics receives $4.2M milestone payment - MSN
Form 13G Coya Therapeutics For: 12 March By Investing.com - Investing.com Australia
Dr. Reddy's takes 9.7% stake in Coya Therapeutics (COYA) via subsidiary - Stock Titan
BTIG Maintains Coya Therapeutics (COYA) Buy Recommendation - MSN
Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday - MarketBeat
Is Coya Therapeutics Inc. impacted by rising ratesMarket Trend Report & Intraday High Probability Alerts - baoquankhu1.vn
Aug Reactions: Is Coya Therapeutics Inc impacted by rising ratesLayoff News & Technical Buy Zone Confirmations - baoquankhu1.vn
Stock Analysis: Is Coya Therapeutics Inc impacted by rising rates2025 Market WrapUp & AI Enhanced Trading Signals - baoquankhu1.vn
Aug Mood: Is Coya Therapeutics Inc benefiting from innovation trendsEarnings Overview Report & AI Driven Stock Reports - baoquankhu1.vn
COYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
New Highs: Is Coya Therapeutics Inc impacted by rising rates - baoquankhu1.vn
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Should I buy Coya Therapeutics Inc. stock nowGDP Growth & Real-Time Sentiment Analysis - mfd.ru
Coya Therapeutics, Inc. (COYA) upgraded to buy: What does it mean for the stock? - MSN
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
COYA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
What’s the RSI of Coya Therapeutics Inc. stockJuly 2025 Levels & Fast Entry and Exit Trade Plans - mfd.ru
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar - Defense World
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - MarketBeat
Coya Therapeutics (COYA) Receives Buy Rating from Jason Kolbert - GuruFocus
COYA Should I Buy - Intellectia AI
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):